(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one

• ChemBase编号: 119603
• 分子式: C38H72N2O12
• 平均质量: 748.98448
• 单一同位素质量: 748.50852575
• SMILES: [C@@H]1([C@@H]([C@H](C[C@H](O1)C)N(C)C)O)O[C@@H]1[C@H]([C@H]([C@H](C(=O)O[C@H]([C@]([C@@H]([C@@H](N(C[C@@H](C[C@]1(O)C)C)C)C)O)(O)C)CC)C)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(OC)C)C
• Canonical SMILES: CC[C@@H]1OC(=O)[C@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@@H]([C@](C2)(C)OC)O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C[C@H](CN([C@H]([C@H]([C@]1(C)O)O)C)C)C)(C)O
• InChI: InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
• InChIKey: MQTOSJVFKKJCRP-BICOPXKESA-N

名称和登记号

名称

• IUPAC标准名: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
• IUPAC传统名: azithromycin; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-2-ethyl-3,4,10-trihydroxy-13-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
• 商标名: Zithromax, Azithrocin, Azin
• 别名: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one Dihydrate; CP-62993; XZ-450; Azitrocin; Ribotrex; Sumamed; Trozocina; Zithromaz; Zitromax; Azithromycin Dihydrate; 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A; Azithromycin; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-3,4,10-trihydroxy-13-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethylt etrahydro-2H-pyran-2-yl)oxy)-3,5,6,8,10,12,14-heptameth yl-1-oxa-6-azacyclopentadecan-15-one; Trezid; Zithromax; Azithromycin

登记号

• CAS号: 83905-01-5; 117772-70-0
• PubChem SID: 162102992
• PubChem CID: 447043; 55185
• CHEBI ID: 2955
• ATC码: J01FA10; S01AA26
• CHEMBL: 529
• Chemspider ID: 10482163
• DrugBank ID: DB00207
• KEGG ID: D07486
• 美国药典/FDA物质标识码: J2KLZ20U1M
• 维基百科标题: Azithromycin
• Medline Plus: a697037

理论计算性质

• Acid pKa: 12.428324
• 质子受体: 13
• 质子供体: 5
• LogD (pH = 5.5): -4.14965
• LogD (pH = 7.4): -1.2309437
• Log P: 2.4447815
• 摩尔折射率: 194.1082 cm^3
• 极化性: 79.00683 Å^3
• 极化表面积: 180.08 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Chloroform; Ethanol,
• 外观: White Solid
• 熔点: 122-124°C

安全信息

• 保存条件: -20°C Freezer, Under inert atmosphere

药理学性质

• 给药途径: Oral (capsule or suspension), intravenous, ophthalmic
• 生物利用度: 38% for 250 mg capsules
• 排泄: Biliary, renal (4.5%)
• 半衰期: 68 h
• 代谢: Hepatic
• 法定药品分级: Rx-only (US)
• 妊娠期药物分类: B (US); B1 (Australia)
• 美国（FDA）药品许可证: Azithromycin
• 生物活性机理: Protein synthesis inhibitor

产品相关信息

• 应用领域: Antibacterial agent; Macrolide antibiotic

详细说明

Toronto Research Chemicals - A927000

Semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial.

参考文献

• Langtry, H.D., et al.: Drugs, 56, 273 (1998)
• Eur. Pat., 1984, Pfizer, 109 253; CA, 101, 211651, (synth, props)
• Girard, A.E. et al., Antimicrob. Agents Chemother., 1987, 31, 1939; 1948, (props)
• Kovacic-Bosnjak, N. et al., Chromatographia, 1988, 25, 999
• Bright, G.M. et al., J. Antibiot., 1988, 41, 1029, (synth, pharmacol)
• Djokic, S. et al., J. Chem. Res., Synop., 1988, 152, (deriv, cryst struct)
• Laufen, H. et al., Arzneim.-Forsch., 1990, 40, 686, (pharmacol)
• Shepard, R.M. et al., J. Chromatogr., 1991, 565, 321, (hplc)
• Barber, J., Magn. Reson. Chem., 1991, 29, 740, (pmr, cmr)
• Ballow, C.H. et al., Ann. Pharmacother., 1992, 26, 1253, (rev)
• Peters, D.H. et al., Drugs, 1992, 44, 750, (rev)
• Drew, R.H. et al., Pharmacotherapy (Carlisle, Mass.), 1992, 12, 161, (rev)
• Mansoor, G.A. et al., Ann. Intern. Med., 1993, 119, 636, (tox)
• Fortner, J.H. et al., Fundam. Appl. Toxicol., 1993, 21, 164, (tox)
• Langtry, H.D. et al., Drugs, 1998, 56, 273-297, (rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 155
• Awan, A. et al., J.C.S. Perkin 2, 2000, 1645-1652, (pmr, conformn)